Literature DB >> 11425160

Interleukin levels in cerebrospinal fluid from children with neurocysticercosis.

F Aguilar-Rebolledo1, R Cedillo-Rivera, P Llaguno-Violante, J Torres-López, O Muñoz-Hernandez, J A Enciso-Moreno.   

Abstract

No information about the levels of pro-inflammatory interleukins has been described in children with neurocysticercosis (NCC). The levels of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-5, IL-6, and IL-12 in the cerebrospinal fluid from children with NCC were determined by enzyme-linked immunosorbent assay (ELISA). Twelve children with NCC, six with active and six with inactive disease, and six children without NCC were studied. TNF-alpha was undetectable in CSF from controls and five children with inactive NCC, whereas the levels were significantly higher (median 22.1 pg/ml; P = 0.008) in all children with active NCC. Levels of IL-6 were low in active and inactive NCC patients but two subjects with active subarachnoid disease had high levels. IL-5 and IL-12 were not detected. This study shows that high levels of TNF-alpha are present in CSF from children with active NCC. IL-6 levels are higher when infection occurs in the subarachnoid space.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425160     DOI: 10.4269/ajtmh.2001.64.35

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  8 in total

1.  Is the presence of depression independent from signs of disease activity in patients with neurocysticercosis?

Authors:  Sergio Monteiro de Almeida; Solange Aparecida Gurjão
Journal:  J Community Health       Date:  2011-10

2.  Suicide risk and prevalence of major depressive disorder (MDD) among individuals infected with HIV-1 subtype C versus B in Southern Brazil.

Authors:  Sergio Monteiro de Almeida; Francisco Jaime Barbosa; Rujvi Kamat; Ana Paula de Pereira; Sonia Mara Raboni; Indianara Rotta; Clea Elisa Ribeiro; Mariana Cherner; Ronald J Ellis; Joseph Hampton Atkinson
Journal:  J Neurovirol       Date:  2016-07-18       Impact factor: 2.643

3.  Neurocysticercosis: local and systemic immune-inflammatory features related to severity.

Authors:  Brenda Sáenz; Agnes Fleury; Anahí Chavarría; Marisela Hernández; José C Crispin; María I Vargas-Rojas; Gladis Fragoso; Edda Sciutto
Journal:  Med Microbiol Immunol       Date:  2011-06-23       Impact factor: 3.402

4.  Immune response in symptomatic and asymptomatic neurocysticercosis.

Authors:  Avantika Verma; Kashi N Prasad; Satyanarayana S Cheekatla; Kishan K Nyati; Vimal K Paliwal; Rakesh K Gupta
Journal:  Med Microbiol Immunol       Date:  2011-05-01       Impact factor: 3.402

5.  Steroid-sparing agents for the treatment of inflammation in complicated neurocysticercosis.

Authors:  Pria Anand; Shibani S Mukerji; Jesse Thon; Shauna Gunaratne; Tracey A Cho; Nagagopal Venna
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-08-20

6.  Taenia solium and Taenia crassiceps: miRNomes of the larvae and effects of miR-10-5p and let-7-5p on murine peritoneal macrophages.

Authors:  Abraham Landa; Luz Navarro; Alicia Ochoa-Sánchez; Lucía Jiménez
Journal:  Biosci Rep       Date:  2019-11-29       Impact factor: 3.840

7.  TNF-α blockade suppresses pericystic inflammation following anthelmintic treatment in porcine neurocysticercosis.

Authors:  Siddhartha Mahanty; Miguel A Orrego; Carla Cangalaya; M Paz Adrianzen; Gianfranco Arroyo; Juan Calcina; Armando E Gonzalez; Héctor H García; Cristina Guerra-Giraldez; Theodore E Nash
Journal:  PLoS Negl Trop Dis       Date:  2017-11-30

8.  Etanercept to Control Inflammation in the Treatment of Complicated Neurocysticercosis.

Authors:  Theodore E Nash; JeanAnne M Ware; Christina M Coyle; Siddhartha Mahanty
Journal:  Am J Trop Med Hyg       Date:  2019-03       Impact factor: 2.345

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.